Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including NEWTON, Mass., Dec. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 4,800 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of November 30, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
马萨诸塞州牛顿，2024年12月2日 /PRNewswire/ -- karyopharm therapeutics公司（纳斯达克：KPTI），一家领先创新癌症疗法的商业阶段药品公司，今天宣布公司向两名新聘员工授予总计4,800个限制性股票单位（RSUs）。这些RSU奖励于2024年11月30日（“授予日期”）根据公司2022年诱导股票激励计划（已修订）授予，作为根据纳斯达克上市规则5635(c)(4)与karyopharm就业的新员工进入雇佣关系的重要诱因。
Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable RSU agreement).
每个RSU奖励将在三年内逐渐归属，其中33 1/3%的RSU奖励下的股份将在授予日期的连续三个周年纪念日归属。每个RSU奖励的归属取决于员工在适用的归属日期时，继续作为Karyopharm的员工或其他服务提供者。此外，如果在"控制变更事件"的首次周年纪念日之前或当天，员工因"正当理由"主动辞职或因Karyopharm的"非因"辞退（相关术语在适用的RSU协议中有定义），则每个RSU奖励将立即可全面行使。
About Karyopharm Therapeutics
关于Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics公司（纳斯达克：KPTI）是一家商业阶段的药品公司，致力于开创新型癌症疗法，其动力来自对癌症患者非凡的力量和勇气的信仰。自成立以来，Karyopharm一直是口服化合物领域的行业领导者，涉及核蛋白输出失调，这是癌症发生的基本机制。Karyopharm的首个口服输出蛋白1（XPO1）抑制剂和首创药物XPOVIO（西立诺司）在美国获批，由公司在三个肿瘤治疗适应症中销售。它还在越来越多的非美国领土和国家，包括欧洲、英国（作为NEXPOVIO）和中国，获得了各种适应症的监管批准。Karyopharm专注于多种高度不满足需求的癌症适应症，包括多发性骨髓瘤、子宫内膜癌、骨髓纤维化和弥漫大B细胞淋巴瘤（DLBCL）。有关我们的人员、科学和管线的更多信息，请访问 请在LinkedIn和X上关注我们，账号是@karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的注册商标。
SOURCE Karyopharm Therapeutics Inc.
来源：karyopharm therapeutics公司
